Compare Incyte Corporation (INCY) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marriott International Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Marriott International Inc trades at $349.51 (market cap $91.14B). The key difference: Marriott International Inc is far larger — about 3.7× Incyte Corporation's market cap, and Marriott International Inc pays a 0.84% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MAR | |
|---|---|---|
Market Cap | $24.54B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $402.54 |
52-Week Low | $81.61 | $259.04 |
Enterprise Value | $20.04B | $108.45B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Marriott International (MAR) trades at $355.34, up 1.98% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 9.62% net income margin and robust cash flow from operations of $3.21B in 2025, though its valuation remains elevated with a P/E of 36.18. Recent news highlights dividend declarations and AI-driven booking tools, while rising debt levels and Middle East weakness present challenges.
The outlook is mixed; analyst consensus leans bullish with a $387.31 price target, but high valuation and increasing debt-to-asset ratio (58.83% in 2025) cap upside potential. Key risks include regional volatility and competitive pressures, while fee revenue growth and a record pipeline offer opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
